文献速递血栓与止血

FVIII抑制物在凝血酶原时间检测中显示FV中和活性

FVIII inhibitors display FV-neutralizing activity in the prothrombin time assay.
PubMed 文献 · J Thromb Haemost · 2021-05-20

本研究基于FV与FVIII约40%的同源性,假设FVIII中和抗体可交叉反应FV。用重组患者来源FVIII中和抗体筛查,发现抗A2域抗体NB11B2有FV中和活性;9例同种免疫HA抑制物血浆有FV中和活性,2例自身免疫样本无。结构分析可解释交叉反应,但FV中和是否参与出血倾向需进一步研究。

要点

  • 抗FVIII A2域抗体NB11B2可交叉中和FV活性。
  • 9例同种免疫HA抑制物血浆有FV中和活性,2例自身免疫样本无。
  • FV与FVIII表面同源性可解释交叉反应。

核心结论

  • FVIII抑制物中的抗A2域抗体可在凝血酶原时间检测中显示FV中和活性。
  • 同种免疫HA抑制物患者血浆中可检测到FV中和活性,而自身免疫样本中未检测到。
  • FV中和是否参与HA患者出血倾向尚需进一步研究。

研究设计与样本

  • 基于FV与FVIII约40%同源性,筛查一组重组患者来源FVIII中和抗体对FV的交叉反应。
  • 用一期凝血法检测FV和FVIII活性,并进行结构分析。
  • 检测多例HA抑制物患者血浆样本的FV中和活性。

主要发现

  • 抗FVIII A2域抗体NB11B2检测到FV中和活性。
  • 9例同种免疫HA抑制物血浆样本有FV中和活性。
  • 2例自身免疫HA抑制物血浆样本无FV中和活性。
  • FV与FVIII表面结构相似性可解释抗A2抗体及患者样本的交叉反应。

临床怎么用

  • HA抑制物患者血浆中FV中和活性可能影响凝血酶原时间检测结果解读。
  • 对HA抑制物患者,需考虑FV交叉中和对抗体治疗和出血评估的潜在影响。

局限性

  • FV中和是否参与HA患者出血倾向尚未确定,需进一步研究。
  • 自身免疫样本仅2例,同种免疫样本9例,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The coagulation factors (F)V and VIII are homologous proteins that support hemostasis through their regulation of FX activity. Hemophilia A (HA) patients have reduced FVIII activity and a prolonged bleeding time that is corrected through the administration of exogenous FVIII. Around one-third of severe HA patients develop FVIII neutralizing antibodies, known as "inhibitors," which neutralize FVIII activity and preclude them from further FVIII therapy. OBJECTIVES: We hypothesized that, based on the degree of homology between FV and FVIII (~40%), FVIII-neutralizing antibodies could cross react with FV. To test this hypothesis, a panel of recombinant, patient-derived, FVIII-neutralizing antibodies were screened for cross-reactivity against FV. METHODS: Factor V and FVIII activity was measured using one-stage clotting assays; structural analysis was carried out using a structural approach. RESULTS: We detected FV neutralizing activity with the anti-FVIII A2 domain antibody NB11B2. Because this antibody was derived from an HA inhibitor patient, FV-neutralizing activity was then evaluated in a number of HA inhibitor patient plasma samples; nine alloimmune samples had FV-neutralizing activity whereas no FV neutralizing activity was found in the two autoimmune samples available. We next examined the degree of surface homology between FV and FVIII and found that structural similarity could explain the cross reactivity of the anti-A2 antibody and likely accounts for the cross reactivity we observed in patient samples. CONCLUSIONS: Although this novel observation is of interest, further work will be needed to determine whether FV neutralization in HA patient samples contributes to their bleeding diathesis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Arsiccio A, Beavis J, Raut S, et al. FVIII inhibitors display FV-neutralizing activity in the prothrombin time assay. J Thromb Haemost. 2021. PMID: 33914406. doi:10.1111/jth.15355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。